Clinical Trial Update: Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating Ixmyelocel-T for heart failure due to dilated cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Heart Failure

Drugs mentioned

• Cardiac Repair Cell (CRC) Treatment (ixmyelocel-t)
• Ixmyelocel-T (Ixmyelocel-T)

Snippet

Sponsor: Vericel Corporation | Conditions: Dilated Cardiomyopathy | Phase 2 | Status: COMPLETED